By Fineline Cube 
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for 2026. In the first half of 2026 (2026H1), the Company recorded revenue of RMB 20.442 billion, a year‑on‑year (YOY) increase of 4.75%, while profit attributable to shareholders, net of non‑recurring gains and losses, reached RMB 1.144 billion, up 19.09% YOY — evidence that innovation and globalization are delivering accelerating earnings quality.
2026H1 Financial Highlights
| Metric | 2026H1 | YOY Change |
|---|---|---|
| Revenue | RMB 20.442B | +4.75% |
| Net Profit (ex non‑recurring items) | RMB 1.144B | +19.09% |
| Innovative Drug Revenue | RMB 4.911B | +13.84% (33.21% of pharma segment) |
| R&D Investment | RMB 3.247B | +25.66% |
| Overseas Revenue (ex‑Mainland) | RMB 6.379B | +16.45% |
Innovation Engine
- R&D Focus: 81.61% of total R&D investment is directed at innovative drugs, concentrated on pipelines including HLX43, HLX22, GR1803, FXR0906, next‑generation small molecules, radiopharmaceuticals, and other cutting‑edge technology platforms.
- Approval Momentum:20 indications across 7 innovative drugs were approved domestically and overseas during the period, marking a phase of intensive approvals and value realisation:
- Hansizhuang (serplulimab): New China approval in perioperative gastric cancer, plus three additional EU first‑line approvals in squamous NSCLC, esophageal squamous‑cell carcinoma, and non‑squamous NSCLC
- Hanbeiyou (pertuzumab): Successive marketing approvals in the EU and China
- Fumaining (luvometinib): New indication for relapsed/refractory Langerhans‑cell histiocytosis (LCH) in patients aged two and older following systemic therapy
Globalization Engine
- International Revenue: Business revenue from regions outside Chinese mainland and other countries reached RMB 6.379 billion, up 16.45% YOY.
- Out‑Licensing: Subsidiary Shanghai Henlius entered strategic partnerships with Eisai and Abbott to out‑license serplulimab, extending the franchise’s global footprint.
- Alzheimer’s Option: Fosun Pharma signed a global exclusive option agreement with AriBio for AR1001, an investigational Alzheimer’s disease drug, with plans to expand rights to key markets including the US, Europe, and Japan.
Market Impact & Outlook
- Earnings Quality: Profit growth of 19.09% versus revenue growth of 4.75% signals a favourable mix shift toward higher‑margin innovative drugs, now 33.21% of pharmaceutical segment revenue.
- Pipeline Depth: The 25.66% step‑up in R&D spend — overwhelmingly innovation‑focused — positions Fosun Pharma for a sustained approval cycle across oncology, rare disease, and next‑generation modalities.
- Global Monetisation: Overseas growth of 16.45% plus high‑profile deals with Eisai, Abbott, and AriBio demonstrate that globalization is transitioning from strategy to measurable earnings contribution.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding revenue trends, pipeline milestones, and international expansion for Fosun Pharma. Actual results may differ due to risks including regulatory approvals, partnership execution, and competitive dynamics.-Fineline Info & Tech